cannabigerol

Cannabigerol is a high affinity α±2-adrenergic receptor agonist, moderate affinity 5-HT1A receptor antagonist, and low affinity CB1 receptor antagonist ; also binds to the CB2 receptor; it can relieve interocular pressure, which may be of benefit in the treatment of glaucoma.

CBGAQ, an analytical reference standard, is an oxidative quinone derivative of cannabigerolic acid (CBGA), designed for research and forensic applications.

CBGB, a butylated form of cannabigerol, serves as an analytical reference standard due to its structural similarity to known phytocannabinoids. Designed for research and forensic applications, this compound offers a specific framework for scientific examination and analytical assessment.

cyclo-Cannabigerol (cyclo-CBG) is the primary metabolite of Cannabigerol formed via cytochrome P450 metabolism. cyclo-Cannabigerol exhibits mild anti-inflammatory activity.

Cannabigerolic acid (CBGA) is a key compound in the biosynthesis of phytocannabinoids, a precursor to various phytocannabinoids, protects against human infections, and can be used in the study of epilepsy.

Sesquicannabigerol is classified as a phytocannabinoid.

Sesquicannabigerolic acid is a compound classified as a phyto cannabinoid.

IL-1β-IN-2, a cannabigerol derivative, serves as a potent inhibitor of IL-1β, exhibiting anti-inflammatory and pain-resolving properties [1].